Akili Inc

Akili, Inc. is a digital medicine company, which engages in the development of cognitive treatments through technologies. Its leveraging technologies designed to directly target the brain establishes a new category of medicine that is validated through clinical trials like a drug or medical device, but experienced like entertainment. The company is headquartered in Boston, MA.

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q3 2024

Akili Inc reports strong Q4 performance, focuses on ADHD market

Akili Inc's Q4 2022 earnings call highlighted strong performance in operational efficiency and clinical trial outcomes.
The company's focus on driving adoption of EndeavorRx and engaging older kids in treatment presents growth opportunities.
Challenges include uncertainties in extrapolating findings to adult studies and investigating treatment engagement across subgroups.
Overall, Akili Inc's strategic initiatives position it well for future growth in the ADHD marketplace.

Akili Inc reports robust Q1 performance, poised for ADHD market expansion

Akili Inc's Q1 2023 showcased strong performance and promising results in the mental health treatment space. With a focus on driving adoption and expanding coverage for Endeavor Rx, Akili aims to solidify its position in the ADHD market. The company's well-funded status and unique technology provide a strong foundation for future growth.

Akili Inc reports flat Q2 revenue, eyes FDA OTC designation

Akili Inc faced revenue challenges in Q2 2023 due to insurance issues but maintained a strong cash position supporting operations until Q1 2025.
The launch of EndeavorOTC for adults with ADHD and its potential FDA OTC designation present growth opportunities for Akili.
Despite challenges, Akili's diversified product portfolio, including EndeavorRx, positions the company well for future market expansion and revenue growth.

Akili Inc reports 500% revenue growth in Q3 2023

Akili Inc's Q3 2023 earnings call showcased strong financial performance, strategic shifts towards a nonprescription model, and a focus on improving unit economics. The company's reaffirmed financial guidance, collaborations, and regulatory progress indicate a positive outlook. Challenges around customer acquisition and market competition were also highlighted.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Akili, Inc. is a digital medicine company, which engages in the development of cognitive treatments through technologies. Its technologies are designed to directly target the physiology of the brain. The company was founded by W. Edward Martucci II and Adam Gazzaley in December 2020 and is headquartered in Boston, MA.

Akili, Inc. (NASDAQ:AKLI ) Q3 2023 Earnings Conference Call November 9, 2023 4:30 PM ET Company Participants Caty Reid - Vice President Marketing & Communications Matt Franklin - President & Chief Operating Officer Scott Kollins - Chief Medical Officer Santosh Shanbhag - Chief Financial Officer Conference Call Participants Vikram Purohit - Morgan Stanley Charles Rhyee - TD Cowen Rahul Rakhit - LifeSci Capital Operator Good afternoon, ladies and gentlemen and welcome to the Akili Interactive Labs Third Quarter 2023 Earnings Call. [Operator Instructions] This call is being recorded on Thursday, November 9, 2023.

Akili, Inc. (AKLI) Q3 2023 Earnings Call Transcript

BOSTON--(BUSINESS WIRE)--Akili Reports Third Quarter 2023 Financial Results and Provides Business Update.

Akili Reports Third Quarter 2023 Financial Results and Provides Business Update

BOSTON--(BUSINESS WIRE)--Akili to Host Third Quarter Financial Results Conference Call on Thursday, November 9 at 4:30 p.m.

Akili to Host Third Quarter Financial Results Conference Call and Webcast on Thursday, November 9 at 4:30 p.m. ET

BOSTON--(BUSINESS WIRE)--Akili, Inc. (Nasdaq: AKLI), the leading digital medicine company behind EndeavorOTC™, today released results from a new study examining the ways in which ADHD impacts the U.S. workforce. Akili engaged Wakefield Research to survey 500 employees with ADHD to better understand the experience of working with ADHD, as well as 500 managers to explore how prepared workplaces are to support employees with ADHD. The study found that nearly all employees with ADHD (97%) think the.

Employees with ADHD Aren't Reaching Their Full Potential at Work, Akili Study Finds

BOSTON--(BUSINESS WIRE)--Akili, Inc. (Nasdaq: AKLI), a leading digital medicine company, today announced that Eddie Martucci transitioned to the role of Board chair, and Matt Franklin has been appointed to serve as president and CEO of the company and as a member of its board of directors, effective October 5, 2023. Martucci replaces former Board chair, Chamath Palihapitiya, who has resigned from the Board, effective October 4, 2023. The leadership transition follows the company's announcement.

Akili Announces Leadership Transition

BOSTON--(BUSINESS WIRE)--Akili Releases EndeavorOTC on Android™ Devices, Expanding Treatment Access for Millions of Adults with ADHD.

Akili Releases EndeavorOTC™ on Android™ Devices, Expanding Treatment Access for Millions of Adults with ADHD

BOSTON--(BUSINESS WIRE)--Akili plans transition to non-Rx business, increasing patient access to clinically-proven non-drug treatments and reducing reliance on intermediaries.

Akili Announces Business Transformation, Focusing on Non-prescription Model

Akili, Inc. (NASDAQ:AKLI ) Q2 2023 Earnings Conference Call August 10, 2023 4:30 PM ET Company Participants Julie DiCarlo - Senior Vice President, Communications Eddie Martucci - Chief Executive Officer Matt Franklin - President and Chief Operating Officer Santosh Shanbhag - Chief Financial Officer Scott Kollins - Chief Medical Officer Conference Call Participants Judah Frommer - Credit Suisse Gus Paul - Morgan Stanley Rahul Rakhit - LifeSci Capital Operator Good afternoon, ladies and gentlemen, and welcome to the Akili, Inc. Second Quarter 2023 Earnings Conference Call. [Operator Instructions] This call is being recorded on Thursday, August 10, 2023.

Akili, Inc. (AKLI) Q2 2023 Earnings Call Transcript

BOSTON--(BUSINESS WIRE)--Akili Reports Second Quarter 2023 Financial Results and Provides Business Update.

Akili Reports Second Quarter 2023 Financial Results and Provides Business Update

BOSTON--(BUSINESS WIRE)--Akili, Inc. (Nasdaq: AKLI), a leading digital medicine company, will host a conference call and webcast to review its financial and operating results for the second quarter of 2023 on Thursday, August 10, 2023, at 4:30 p.m. ET. A live audio webcast of the conference call and presentation will be available at www.akiliinteractive.com under Investor Relations, Events & Presentations. An archived version of the webcast will be available on the company's website followi.

Akili to Host Second Quarter Financial Results Conference Call and Webcast on Thursday, August 10 at 4:30 p.m. ET

BOSTON--(BUSINESS WIRE)---- $AKLI #ADHD--Adults with ADHD can now improve their attention & focus with a new clinically-proven mobile video game treatment. Available now in the iOS App Store.

Akili Releases EndeavorOTCTM Video Game Treatment to Improve Attention in Adults with ADHD

BOSTON--(BUSINESS WIRE)---- $AKLI #ADHD--Akili To Presents Clinical Data from Pivotal Trial of Video Game Treatment in Adolescents with ADHD at Upcoming Scientific Meetings.

Akili to Present Clinical Data from Pivotal Trial of Video Game Treatment in Adolescents with ADHD at 2023 ASCP Annual Meeting and Elevate Psych Congress

BOSTON--(BUSINESS WIRE)---- $AKLI #ADHD--Akili, Inc. (Nasdaq: AKLI), a leading digital medicine company, today reported its financial results for the quarter ended March 31, 2023, and provided an update on business progress. “We're seeing steady, increasing uptake of EndeavorRx in the pediatric market,” said Eddie Martucci, chief executive officer of Akili. “With the submission of our EndeavorRx adolescent label expansion data to the FDA and positive results from our pivotal trial in adults with ADHD, we now h.

Akili Reports First Quarter 2023 Financial Results and Provides Business Update

BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Akili Announces Topline Results of the STARS-ADHD-Adult Clinical Trial.

PureTech Founded Entity Akili Announces Adults with ADHD See Significant Improvements in Attention, ADHD Symptoms, and Quality of Life in Clinical Trial of Akili's EndeavorRx® Video Game-Based Therapeutic

Akili (NASDAQ: AKLI ) stock is gaining on Wednesday after the company's video game treatment showed success in reducing ADHD in adults. Akili's EndeavorRx treatment uses video games to treat patients who deal with the effects of ADHD.

Why Is Akili (AKLI) Stock Up 21% Today?

BOSTON--(BUSINESS WIRE)---- $AKLI #ADHD--Adults with ADHD improve their attention and quality of life using EndeavorRx video game treatment in clinical trial.

Adults with ADHD See Significant Improvements in Attention, ADHD Symptoms, and Quality of Life in Clinical Trial of Akili's EndeavorRx® Video Game-Based Therapeutic

BOSTON--(BUSINESS WIRE)---- $AKLI #ADHD--Akili, Inc. (Nasdaq: AKLI), a leading digital medicine company, will host a conference call and webcast to review its financial and operating results for the first quarter of 2023 on Thursday, May 11, 2023, at 4:30 p.m. ET. A live audio webcast of the conference call and presentation will be available at www.akiliinteractive.com under Investor Relations, Events & Presentations.

Akili to Host First Quarter Financial Results Conference Call and Webcast on Thursday, May 11 at 4:30 p.m. ET

Akili, Inc. (NASDAQ:AKLI ) Q4 2022 Earnings Conference Call March 7, 2023 4:30 PM ET Company Participants Julie DiCarlo - Senior Vice President of Communications Eddie Martucci - Co-Founder, CEO & Director Matthew Franklin - President & COO Scott Kollins - Chief Medical Officer Santosh Shanbhag - CFO & Treasurer Conference Call Participants Nicholas Japhet - Credit Suisse Michael Cherny - BofA Securities Rahul Rakhit - LifeSci Capital Vikram Purohit - Morgan Stanley Marie Thibault - BTIG Operator Greetings, and welcome to the Akili Fourth Quarter 2022 Earnings Call. [Operator Instructions] As a reminder, this conference is being recorded.

Akili, Inc. (AKLI) Q4 2022 Earnings Call Transcript

BOSTON--(BUSINESS WIRE)--Akili, Inc. (Nasdaq: AKLI), a leading digital medicine company, today reported its financial results for the quarter and full year ended December 31, 2022, and provided an update on business progress. “We have established a focused and efficient operating model that I believe best allows us to realize our goal of making EndeavorRx part of routine clinical care,” said Eddie Martucci, chief executive officer of Akili.

Akili Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

BOSTON--( BUSINESS WIRE )--Akili, Inc. (Nasdaq: AKLI), a leading digital medicine company, will host a conference call and webcast to review its financial and operating results for the fourth quarter and full year of 2022 on Tuesday, March 7, 2023 at 4:30 p.m. ET.

Akili to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call and Webcast on Tuesday, March 7 at 4:30 p.m. ET

BOSTON--( BUSINESS WIRE )--Akili, Inc. (Nasdaq: AKLI), a leading digital medicine company, will participate in the Cowen 43rd Annual Health Care Conference in Boston next month.

Akili to Participate in the Cowen 43rd Annual Health Care Conference

BOSTON--( BUSINESS WIRE )--Akili, Inc. (Nasdaq: AKLI), a leading digital medicine company, will participate in the Biotech Showcase and Solebury 1x1 Management Access Conference, both happening alongside the J.P. Morgan Healthcare Conference in San Francisco next week.

Akili to Champion Digital Therapeutics in Conjunction with J.P. Morgan Healthcare Conference

ABVC BioPharma

Bellerophon Therapeutics

Eloxx Pharmaceuticals Inc

Orchard Therapeutics plc - ADR

Hot penny stocks with news to watch this week. The post 5 Hot Penny Stocks Exploding After News This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

5 Hot Penny Stocks Exploding After News This Week

BOSTON--( BUSINESS WIRE )--Akili, Inc. (Nasdaq: AKLI), a leading digital medicine company, today announced topline results of the STARS-ADHD-Adolescents label expansion study evaluating the efficacy and safety of EndeavorRxⓇ (AKL-T01) in adolescents ages 13-17 with attention-deficit/hyperactivity disorder (ADHD). The pivotal study achieved its predefined primary efficacy outcome, showing statistically significant improvement in attentional functioning after four weeks of treatment. Consistent improvements were also seen in a range of secondary measures of ADHD-related inattention symptoms and functioning. EndeavorRx treatment was generally well-tolerated, with no serious device-related adverse events reported.

Pivotal Trial of EndeavorRxⓇ in Adolescents with ADHD Shows Robust Improvements in Attention and Broader Clinical Outcomes

BOSTON--( BUSINESS WIRE )--Akili, Inc., a leading commercial digital medicine company, today announced the appointment of Scott Kollins, Ph.D., as chief medical officer, effective December 1, 2022. Dr. Kollins will report to Akili's chief operating officer and join the company's executive team.

News for Akili Inc Stock (AKLI)